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Abstract
Background: Peritonitis is responsible for thousands of deaths annually in Germany alone. Even source control (SC)
and antibiotic treatment often fail to prevent severe sepsis or septic shock, and this situation has hardly improved
in the past two decades. Most experimental immunomodulatory therapeutics for sepsis have been aimed at
blocking or dampening a specific pro-inflammatory immunological mediator. However, the patient collective is
large and heterogeneous. There are therefore grounds for investigating the possibility of developing personalized
therapies by classifying patients into groups according to biomarkers. This study aims to combine an assessment of
the efficacy of treatment with a preparation of human immunoglobulins G, A, and M (IgGAM) with individual status
of various biomarkers (immunoglobulin level, procalcitonin, interleukin 6, antigen D-related human leucocyte
antigen (HLA-DR), transcription factor NF-κB1, adrenomedullin, and pathogen spectrum).
Methods/design: A total of 200 patients with sepsis or septic shock will receive standard-of-care treatment (SoC).
Of these, 133 patients (selected by 1:2 randomization) will in addition receive infusions of IgGAM for 5 days. All
patients will be followed for approximately 90 days and assessed by the multiple-organ failure (MOF) score, by the
EQ QLQ 5D quality-of-life scale, and by measurement of vital signs, biomarkers (as above), and survival.
Discussion: This study is intended to provide further information on the efficacy and safety of treatment with IgGAM
and to offer the possibility of correlating these with the biomarkers to be studied. Specifically, it will test (at a descriptive
level) the hypothesis that patients receiving IgGAM who have higher inflammation status (IL-6) and poorer immune
status (low HLA-DR, low immunoglobulin levels) have a better outcome than patients who do not receive IgGAM. It is
expected to provide information that will help to close the knowledge gap concerning the association between the
effect of IgGAM and the presence of various biomarkers, thus possibly opening the way to a personalized medicine.
Trial registration: EudraCT, 2016–001788-34; ClinicalTrials.gov, NCT03334006. Registered on 17 Nov 2017.
Trial sponsor: RWTH Aachen University, represented by the Center for Translational & Clinical Research Aachen
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Background
Peritonitis
In Germany, around 10,000 patients are treated annu-
ally for peritonitis [1]. Owing to the copious blood
supply of the peritoneum, an infection can rapidly
spread to the entire organism, causing potentially
life-threatening damage. Peritonitis is classified as fol-
lows [2]: primary (hematogenic in children, bacterial in
adults, or following tuberculosis or gonorrhea); second-
ary (post-operative, post-traumatic, or due to perfor-
ation); tertiary (owing to immune deficiency, usually
avirulent); quaternary (due to intra-abdominal abscess,
or hospital-acquired or catheter-associated infection);
and specific forms due, e.g., to Candida infection or
chemical effects.
Intra-abdominal infections are treated by standard
methods of surgery and intensive care. As peritonitis can
rapidly lead to bacteremia and sepsis, infectious source
control and antibiotic treatment remain the methods of
choice to limit the spread of bacteria and the secretion of
their toxins. Even after source control and adequate anti-
biotic treatment, severe sepsis or septic shock can occur,
so that the lethality associated with peritonitis is still high
and, despite all medical progress, has hardly been reduced
in the past 20 years. With an overall mortality rate between
30% and 40% depending upon the population observed,
(post-operative) secondary peritonitis remains one of the
deadliest diseases in the intensive care unit (ICU) [3].
Hitherto, most studies of immunomodulatory therap-
ies for sepsis have aimed at blocking, or dampening, a
specific pro-inflammatory immunological mediator
within a large and heterogeneous patient collective.
These—in some cases large-scale—studies generally gave
negative results. The failure of “single-mediator”
strategies appears to have lain in the pleiotropy and re-
dundancy of corresponding mediator/cytokine networks
and in inadequate immunological characterization of the
study patients under treatment. Adequate immuno-
logical characterization of study patients is necessary, as
the justification of immunological interventions
demands evidence of immunological efficiency. This is
especially the case for the highly heterogeneous
collective of sepsis patients, and it lies behind the ur-
gency of identifying biomarkers that allow immuno-
logical characterization and prognostic assessment.
In the future, a “personalized” therapy may be made
possible by classifying patients into groups according to
biomarkers (currently, about 30 medicinal preparations
marketed in Germany require such pre-diagnosis and
another ten recommend it). The use of such tests may
allow better prediction of whether—and in some cases
how—a patient will respond to a given treatment. A fur-
ther important consideration is maintaining the balance
between pro- and anti-inflammatory immune actions,
avoiding over-response on the one hand and immune
exhaustion on the other [4].
In sepsis, biomarkers are used for diagnosis, risk stratifi-
cation, progress-monitoring, and adaptation of therapy.
Apart from unspecific inflammation and acute-phase
markers (leukocyte count; C-reactive protein (CRP)), bio-
markers with high specificity and sensitivity are available:
procalcitonin (PCT) and antigen D-related human
leukocyte antigen (HLA-DR) [5]. The frequently used
CRP is only of limited value in sepsis on account of its
long induction time (up to 48 h) and the persistence of el-
evated levels, both in early diagnosis and for assessment of
the course and prognosis of disease [6, 7]. These conven-
tional markers allow only restricted inferences to be
drawn about the immunological situation in sepsis cases.
The following biomarkers have been identified as be-
ing able to aid decision-making:
– PCT: With its short induction time of 1–2 h and up
to 104-fold increase [8–10], serum PCT possesses
high sensitivity (89–96%) and specificity (78–94%) [7].
It can be used to steer antibiotic treatment [11],
which in a study shortened from 12.9 to 5.8 days [12,
13].
– Interleukin 6 (IL-6): A pro-inflammatory cytokine
expressed by monocytes/macrophages, endothelial
cells, keratinocytes, and fibroblasts. It has a rise time
of only ~ 2 h [14] and is correlated with the severity
of sepsis [15, 16].
– HLA-DR: The standardized measurement of HLA-
DR expression indicates the level of monocyte func-
tions and allows immunological characterization of
the patient. Patients identified as having restricted
immunological function can profit from an immuno-
modulatory therapeutic strategy [17, 18].
– Immunoglobulins (IgG, IgM, IgA): Recent studies
have revealed clear correlations between survival
probability and levels of IgG, IgM, und IgA (singly
or in combination) in severe sepsis and septic shock
[19, 20]. Patients with depressed Ig levels have a
poorer chance of survival. One study revealed a
particularly strong survival advantage (factor 5.2)
when IgG1, IgA, and IgM exceeded the following
values: IgG1 > 300 mg/dl, IgM > 35 mg/dl, IgA > 150
mg/dl [20]). This agrees with other recent study
results on the kinetics of IgM concentration during
the course of sepsis [21].
– Adrenomedullin (ADM): Adrenomedullin has a
vasodilatatory effect and influences several systems
(circulation, heart, hormone secretion, and
respiration [22–24]). It plays a major part in
initiating the hyperdynamic response in early-phase
sepsis, and its level is correlated with the severity of
disease. The available data suggest that the level of
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biologically active ADM may be usable as a bio-
marker for septic shock [25]; further studies are
called for to assess its value.
– NF-κB1: The transcription factor NF-κB1 mediates
the cell’s acute response to pathogenic and inflam-
matory stimuli, activating many of the so-called “im-
mediate early genes” (tissue factors, endothelins,
cytokines) involved in sepsis, and regulating some
500 different genes in all along with the processes of
immune response, cell proliferation, and apoptosis.
The activation of NF-κB1 is believed to be critical
for the initiation of inflammation. One possible rea-
son for the failure of sepsis studies may be traceable
to the genetic polymorphism of NF-kB1 [26–28].
Analysis of NF-κB1 polymorphism is the object of
current research.
– Identification of pathogens from blood and
abdominal secretions (pathogen spectrum). A
standardized analysis of the microbiological pattern
from ascitis and from blood will be performed with
the Curetis Unyvero molecular biology system
(Curetis GmbH; Holzgerlingen, Germany).
Treatment of septic patients is dependent on the
type of microorganism(s) [29] and of resistance(s)
[30]. The effect of IgGAM on different
microorganisms in septic patients will be explored.
For a long time, abdominal sepsis was thought to be
purely hyperinflammatory in nature. It is now known that
every hyperinflammation induces a compensatory hypoin-
flammation [31]. These do not alternate; rather, hypo- and
hyperinflammation can overlap in time and sepsis is to be
regarded as a dysregulation of inflammation.
Study treatment
The efficacy of treatment with IgGAM (Pentaglobin®)
was demonstrated in a double-blind study of 56 patients
with peritonitis accompanied by severe sepsis or septic
shock [32]. A meta-analysis of 560 patients in eight stud-
ies revealed a pooled relative risk of mortality of 0.64, and
the pooled effect of seven studies on 932 patients was 0.85
[33]. More recent studies have shown that a depressed
IgM level in sepsis (including peritonitis) is associated
with poorer outcomes [34]. In severe pneumonia, the
CIGMA study showed that IgM substitution reduced the
mortality in the subgroup of patients with low IgM or high
CRP ([35]).
Despite this, the available information is inadequate
[36], so that expert recommendation (on the basis of the
meta-analysis [33]) corresponded only to level C in the
German sepsis guideline. For peritonitis no recent data
are available, and the present study is intended to fill this
gap. It is also intended to investigate the possible rele-
vance of various biomarkers (see above) in identifying
subgroups of patients who could especially profit from
treatment with IgGAM. This could provide the basis for
a large-scale (phase III) study. The biomarker may also
help in designing personalised adjuvant treatments with
IgGAM in the indication of peritonitis.
Risks and benefits
IgGAM has an immunoregulatory effect, i.e., hyper- und
hypoinflammation are both enhanced. Pathogens are elimi-
nated and endotoxins are neutralised. Studies [32, 37] have
shown that the administration of IgGAM as an adjuvant
treatment can improve the survival of peritonitis patients.
Immunoglobulins are natural, human proteins, the
clinical use of which has been well established since the
1980s [38].We consider the high dose level to be justi-
fied on account of the extremely poor condition of these
patients (Sequential Organ Failure Assessment (SOFA)
score ≥ 8 [39]); the lower levels given in the Specification
of Product Characteristics [40] are “recommendations”
that may “serve as a guide”. In earlier studies [32, 35]
the higher dose levels to be used in the present study
were also successfully applied.
The risk of viral infection is considered to be negligible
and not to warrant testing beyond the manufacturer’s
standard procedures. The only invasive study tests involve
drawing a total of 50ml blood over 5 days. Thus, the over-
all risk to the patients is very small and is favourable in
the light of the expected possible benefits to the study pa-
tients and the gain in knowledge to be acquired.
Objectives and assessment criteria
The purpose of this study is to evaluate the adjuvant
IgGAM treatment in respect of:
a) An improvement of the outcome for the patient’s
peritonitis. This will be investigated by using scores
such as the multiple organ failure (MOF) score [41]
(as modified [42], Additional file 1) and Sequential
Organ Failure Assessment (SOFA) score as well as
the Mannheim Peritonitis Index (MPI; a validated
index used commonly in Germany [43] and in
several other European countries [44]) and survival
data.
b) Identification of biomarkers (Ig level, PCT, IL-6,
HLA-DR, NF-κB1, ADM, pathogen spectrum) to
identify patient subpopulations that profit most
from treatment with IgGAM. Such patients will
comprise the basis for a further study, which will be
a randomized, controlled, double-blind trial to dem-
onstrate the value of this treatment.
c) Furthermore, these biomarkers are expected to help
with developing a “personalized” adjuvant therapy
with IgGAM in the indication of peritonitis.
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Primary endpoint
Improvement of the mean MOF score on day 7
expressed as the difference in MOF score between day 7
and day 0 (Δ [MOF Day 7 − Day 0]). The analysis will
be adjusted for the baseline MOF score (day 0). The pri-
mary analysis will be performed with the PP population
(see definition below).
The MOF score is determined in the morning, with
the following scoring for each organ (lungs, heart, kid-
neys, liver, blood): normal function, 0; dysfunction, 1; in-
dividual organ failure, 2. An aggregate score greater than
4 implies multi-organ failure. Patients who die will be
assigned the maximum score of 10 and will be included
in the population assessment.
Secondary endpoints
– Overall 28-day survival
– Overall 90-day survival
– Improvement in MOF score on day 5
– Relative number of patients with multi-organ failure
(i.e., > 4 MOF points) on day 7.
Additional study variables
– Time course of the biomarkers (PCT, IL-6, HLA-DR,
ADM, IgM, IgG, IgA), the SOFA score, the MPI, the
surrogate variables for organ dysfunction and survival
according to Heyland et al. [45], and vital signs.
– Influence of the biomarkers NF-κB1, ADM, and
pathogen spectrum upon the improvement of the
mean MOF score on day 7.
– Comparison of the MOF score with other scores,
such as the SOFA score, for assessment of organ
dysfunction.
Methods/design
Study design
This multicentric, prospective clinical study will be
conducted according to a controlled, randomized,
two-arm, parallel-group design. No blinding will be
performed. The study is planned to be conducted in
14 centers in Germany and Austria.
Study patients
The following eligibility criteria were selected to include
patients of either sex, with abdominal surgery developing
peritonitis, with severe sepsis (SOFA score), IL-6 (sustained
inflammation), and with concurrent guideline-appropriate
therapy (timelines of source control, IgGAM treatment,
and antibiosis). We decided to use the SOFA score as an
inclusion criterion to assure a homogenous patient popula-
tion with a certain level of disease severity. Additionally,
the SOFA score is used worldwide, being included in the
current Sepsis Guideline; this makes it more common
today on ICUs [46], which in turn simplifies the identifica-
tion of potential study patients. The MOF score is less
commonly applied, but it focuses on the failure of different
organ systems. Besides scoring, the MOF score also allows
identification of the organ system that benefits most from
the IgGAM treatment and identification of multi-organ
failure with an aggregated score greater than 4, which
makes it very well suited to serve as a primary outcome
criterion [42]. The eligibility criteria include only the IL-6
and not the immunoglobulin levels, since short-term im-
munoglobulin determination cannot be implemented in
practice as it is not available 24 h a day at all study sites.
Inclusion criteria
1. Peritonitis.
2. Time of source control intervention: within 6 h of
determination of the indication (defined as the time
of placing the patient on the list for operation or
minimally invasive measure).
3. Sepsis and septic shock (according to the current
sepsis guideline [47]).
4. SOFA score of 8 or above.
5. IL-6 level of 1000 pg/ml or above.
6. Antibiotic treatment begun within 12 h after entry
to the ICU.
7. Written informed consent by the patient or if
appropriate by his/her legal representative or the
consulting physician.
Exclusion criteria
1. Life expectancy less than 90 days because of
medical circumstances that are not related to the
patient’s peritonitis or sepsis/septic shock.
2. Pregnancy, breast-feeding.
3. Age below 18 years.
4. Known chronic kidney insufficiency requiring
dialysis (creatinine ≥ 3.4 mg/dl or creatinine
clearance ≤ 30mL/min/1.73 m2).
5. Pancreatitis or mediastinitis.
6. Body mass index > 40 kg/m2.
7. Presence of any counter-indication against the study
medication.
8. Participation in any other mediation study within
the previous 30 days.
9. A dependency on or a professional relationship with
the sponsor or the investigator.
10. Commitment of the patient to any resident
institution by order of any court or authority.
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Interventions
The control group will receive standard-of-care treat-
ment, i.e., the IgGAM is an add-on treatment in this
study. The use of placebo instead of standard therapy
would further minimize possible bias potential and in-
crease the quality of the study accordingly. Nevertheless,
for reasons of feasibility, we have initially opted for an
open design comparing IgGAM against standard care,
especially since the present study was primarily designed
to serve as a solid basis for a larger blinded follow-up
study; in such a study, placebo controls would be used
to investigate explicitly personalized medicine with
IgGAM and to show an improvement in mortality with
IgGAM treatment. The active study treatment is
IgGAM, a preparation containing human immunoglobu-
lins G, A, and M. The preparation to be provided con-
tains 50 mg/ml human plasma proteins, of which ≥ 95%
are immunoglobulins: IgM 6mg, IgA 6mg, and IgG 38
mg. The IgG subclass distribution is IgG1 ~ 63%, IgG2
~ 26%, IgG3 ~ 4%, IgG4 ~ 7%. IgGAM is administered
by continuous infusion over 5 days at a dose level of 0.4
ml/kg body weight per hour, until a total dose of 7ml/kg
on that day has been reached; administration will then be
stopped and recommenced on the following day, until ad-
ministration has been completed for 5 consecutive days.
Course of the study
The study procedures are summarized in Figs. 1 and 2.
As soon as interventional source control for
peritonitis-induced sepsis is indicated, screening (SCR)
will commence. Patients will be informed about the
study and written informed consent to participate will
be requested by the investigator. If a patient is unable to
give consent, he may be represented by his legal repre-
sentative, such as a court-appointed carer or an autho-
rized proxy. If no legal representative or court-appointed
caregiver is available, then a study-independent consult-
ant physician can provide consent on the patient’s be-
half, though only if a review of the overall circumstances
reveals clear positive evidence that the presumed will of
the patient is in favor of participating in the study. As
soon as the patient is able to consent, the examiner will
inform him about the study, ask for his written consent
and thus give him the opportunity to withdraw consent.
Empirical antibiotic treatment will be started with car-
bapenem or piperacillin/tazobactam; any other antibiotic
must be documented along with the reason for choosing
it. Interventional source control must begin within the 6
h after registration for the operation: successful control
must be documented. Within the first hour after source
control, guideline-compliant initial therapy is to be con-
ducted in the ICU: acquisition of material for microbio-
logical diagnosis, placing of a central vein catheter,
invasive blood-pressure measurement, volume therapy,
and empirical antibiotic treatment as above. Baseline is
defined as the time point immediately after transfer of
the patient to the ICU after interventional source con-
trol (before the first administration of IgGAM). At this
point the inclusion and exclusion criteria will be checked
and the patient, if eligible to participate, will be ran-
domly allocated to the verum arm (133 patients,
standard-of-care treatment plus IgGAM) or the control
arm (67 patients, standard-of-care treatment only). A
computer-generated block randomization list, stratified
by center, with a control:intervention ratio of 1:2 is used.
Block size is not revealed to the centers. Unbiased
randomization is ensured by using a centralized online
system provided and maintained by the sponsor.
For patients in the verum arm, IgGAM will be admin-
istered as described above, starting within 12 h of entry
to the ICU; the day of this first administration is defined
as day 1 (for patients in the control arm, day 1 is the day
when they would have received IgGAM). IgGAM will be
administered on days 1–5. The treatment phase ends on
day 7; follow-up examinations are to be conducted on the
day of discharge from the ICU and on days 28 and 90.
For all patients, the following information will be re-
corded: demography and anamnesis (baseline); concomi-
tant medication up to discharge from the ICU; MPI
(baseline, days 3 and 7); SOFA score (screening, baseline,
days 2, 3, and 7, and at discharge); MOF score (baseline,
days 2–7, and at discharge); vital signs (screening, source
control on day 0, baseline, days 2, 3, and 7, and at dis-
charge); adverse events (baseline to day 7 and at
follow-up); quality of life (using the EQ QLQ 5D ques-
tionnaire; at discharge and on days 28 and 90); duration
of stay in hospital and in the ICU.
Samples will be taken on days 2–5 and 28 for assess-
ment of the following parameters: microbiological
markers from ascites cells, including pH measurement
of ascites, and from blood culture (day 0); NF-κB1 and
ADM (baseline); CRP, PCT, IL-6, HLA-DR, differential
blood count (baseline, days 2, 3, and 7, and at discharge);
Ig status (baseline, days 2–5, and at discharge).
Independent Adjudication Committee
For all patients, the adequacy and the course of periton-
itis treatment (antibiotic treatment and source control)
will be reviewed by an independent committee, the
members of which are not otherwise involved in the
study and will include experts in intensive care, surgery,
and microbiology.
Statistical analysis
Analysis sets
The intent-to-treat (ITT) population will comprise all
patients included in the study. This will also be the
population used for safety analysis. The primary analysis
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of efficacy will be conducted with a subset of the ITT
population comprising only those patients whose treat-
ment was considered by the independent Adjudication
Committee (see above) to have been adequate; this sub-
set we term the per protocol (PP) population.
Primary analysis
The study will investigate the hypothesis that patients
receiving IgGAM who have higher inflammation status
(IL-6 ≥ 1000 pg/ml, CRP ≥ 70mg/L) and poorer immune
status (HLA-DR expression ≤ 8000 molecules per mono-
cyte; IgG1 < 300 mg/dl, IgM < 35mg/dl, IgA < 150mg/dl)
have a better outcome than patients who do not receive
IgGAM. This hypothesis is based on various clinical
studies: Bermejo-Martin et al. [20] demonstrated that the
combined presence of low levels of the endogenous im-
munoglobulins IgG1, IgM, and IgA in plasma is associated
with reduced survival in patients with severe sepsis or sep-
tic shock. In parallel, Welte et al. [35] supported improved
outcome regarding mortality with immunoglobulins in
subsets of sCAP patients with elevated CRP, reduced IgM,
or both. Both studies indicated that the assessment of the
concentrations of these immunoglobulins could improve
the results of treatment with exogenous immunoglobulins
in patients with sepsis.
The primary endpoint (improvement in MOF score on
day 7) will be analyzed by comparing the two treatment
arms using mixed linear models.
A greater improvement of the mean MOF score on day
7 in the IgGAM-treated group by at least 0.8 points is
expected. Afterwards the same analysis will be performed
with the overall ITT population. The dependent variable
will be the change in MOF compared with baseline (in the
primary comparison: between baseline and day 7). Fixed
independent variables will be treatment group and visit;
baseline MOF will be a covariate and study center a ran-
dom effect. Interaction between treatment and visit will
be investigated. Restricted maximum-likelihood estima-
tion and autoregressive covariance structure will be used.
Sensitivity analyses will also be performed.
Secondary analyses
All other analyses will be at the descriptive level; results
will be tabulated and nominal p values calculated for the
ITT and PP populations. Relative survival will be ana-
lyzed by the Kaplan–Meier method. Cox regression
models will be used, with treatment group and baseline
MOF as independent variables. The numbers of patients
with multi-organ failure will be analyzed by Poisson re-
gression. Subgroup analyses are planned, using the sub-
groups ‘normal’ and ‘low’ IgM (cut off < 0.8 g/dl) and
CRP (cut-off ≥ 70mg/dl).
Sample size
The following assumptions are made: significance level
α = 0.05; power = 90%; randomization ratio verum:con-
trol 2:1; in MOF score 3.0 (verum) vs 3.8 points (con-
trol), each with a standard deviation of 1.5 points. A
t-test model led to N = 114 in the active treatment group
and 57 in the control group. To allow for drop-outs
Fig. 1 Course of the study. ICU intensive care unit, IgGAM preparation containing immunoglobulins G, A, and M, MOF multiple organ failure, OP
operation , QoL quality of life
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Fig. 2 SPIRIT figure. For abbreviations see text
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from the PP population, an additional margin of ~ 13%
is allowed, giving N = 133 in the active-treatment group
and 67 in the control group (total 200).
Data management and quality assurance
All data will be collected in an electronic case report
form, including edit checks, developed by a qualified
data manager of the sponsor (RWTH Aachen Univer-
sity). The sponsor will furthermore ensure data valid-
ation, data verification, and compliance through regular
monitoring visits according to ICH-GCP. The investiga-
tor will be required to authorize audits and inspections
by competent surveillance authorities.
Discussion
In recent decades there has been little progress in devel-
oping effective treatments for sepsis and septic shock in
connection with secondary peritonitis. With a survival
rate between 60% and 70% depending on the population
observed, there is a clear unmet need for new ap-
proaches to this problem. Approaches to this have in re-
cent years included the suppression of pro-inflammatory
factors, including anti-TNF, anti-endotoxin, and
anti-IL-6, and interference with the coagulation system,
with, e.g., anti-thrombin III and activated protein C
(drotrecogin alfa) [48–50] but neither could be shown to
have clinically demonstrable efficacy.
In this study the PP population is used for the primary
analysis, i.e., considering only patients for whom it is
confirmed by the independent Adjudication Committee
that they received treatment in respect of the mainstay
of peritonitis treatment, i.e., successful source control
and early adequate antibiotic treatment. These two mea-
sures are a prerequisite for any supportive treatment
such as the application of IgGAM. The correct and
timely application of IgGAM will be also assessed by the
Adjudication Committee. A similar approach for pri-
mary analysis was used by Solomkin et al. [51], in a ran-
domized controlled study of complicated abdominal
infection, for assessment of non-inferiority of eravacy-
cline compared with ertapenem. In that study, of the
541 patients randomized, only 465 patients received ad-
equate treatment and could be included in the prede-
fined primary analysis.
The sample size in the present study is considered ad-
equate to allow demonstration of statistical superiority
of IgGAM over standard-of-care in peritonitis patients
by the criteria of MOF, but is not adequate for mortality
or subgroup analyses. Nevertheless, it is important to
identify subgroups of patients who benefit most from
IgGAM, to allow individualized treatment of these pa-
tients, probably identified by biomarkers assessed in this
trial. The sample size in the present study is probably
too small for such an analysis; however, the study was
primarily designed to serve as a solid base for a larger
blinded follow-up study with placebo controls to investi-
gate explicitly personalized medicine with IgGAM and
to show an improvement in mortality with IgGAM treat-
ment. Another approach, made possible by increasingly
exact and detailed analytical measurements, could be the
adaptation of treatment to the individual patient, i.e.,
“personalized” therapy. For this reason it will be neces-
sary to discover which patients will profit best from im-
munomodulatory treatment, and of which kind. It is
therefore hoped that the present study will provide more
information toward such therapies, by allowing correla-
tions to be established between the patients’ response to
treatment with IgGAM and the presence or absence of
one or more of a number of pre-defined biomarkers.
Trial status
The trial protocol has received a positive vote from the
responsible ethics committee (Ethik-Kommission der
Medizinischen Fakultät des Universitätsklinikums der
RWTH Aachen, EK 156/17), from the German federal
authority for trials involving biomedical products (Pau-
l-Ehrlich-Institut, Langen, PEI 3104/01) and from the
Austrian federal authority for trials (BASG 10621880).
The first patient was recruited in November 2017. This
manuscript is written in accordance with the SPIRIT
Statement (Additional file 2).
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